BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding Outcome of Board Meeting held on March 25, 2026.
BALAXI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The Board of Directors of Balaxi Pharmaceuticals, at its meeting on March 25, 2026, approved the appointment of Mr. Aman Purohit as the new Company Secretary and Compliance Officer of the company, effective from the same date. Mr. Purohit is an Associate Member of ICSI (membership number A59345) with a B.Com (Honours) in Accountancy from the University of Calcutta. He brings around 6 years of post-qualification experience in secretarial compliance, mergers and acquisitions, corporate restructuring, due diligence, fundraising, and strike-off work, having previously served as Company Secretary at Patil Rail Infrastructure Pvt Ltd and Re Sustainability IWM Solutions Ltd. The board meeting ran from 11:45 a.m. to 12:50 p.m. and the signed letter was issued by Managing Director Ashish Maheshwari.
This is a routine KMP-level compliance appointment and should not materially affect the stock price. Shareholders may note that the company has filled a key compliance role, which is a positive governance signal.